

# Contents

## **SECTION 1    DISEASE OF THE AORTA    1–13**

1.1 Aortic Aneurysm.....	1
1.2 Aortic Dissection.....	7

## **SECTION 2    ARRHYTHMIAS    14–95**

2.1 Cardiac Arrest and Sudden Cardiac Death.....	14
2.2 Syncope and Hypotension.....	23
2.3 Torsades.....	28
2.4 Various Ventricular Tachycardias.....	29
2.5 Ventricular Premature Contraction and Ventricular Tachycardia.....	31
2.6 Ventricular Tachycardia Storm.....	33
2.7 AVNRT, AVRT, Mahaim, PJRT.....	34
2.8 Genesis of Cardiac Arrhythmias (Anatomy of Card. System).....	38
2.9 Bradyarrhythmia.....	40
2.10 Brugada Syndrome.....	42
2.11 Catecholaminergic Polymorphic Ventricular Tachycardia.....	44
2.12 Diagnosis of Cardiac Arrhythmias.....	45
2.13 Therapy for Cardiac Arrhythmias.....	50
2.14 Long QT and Short QT Syndromes.....	59
2.15 Premature Atrial Contractions and Atrial Flutter.....	62
2.16 Epicardial Ventricular Tachycardia.....	64
2.17 Therapy of Cardiac Arrhythmia.....	65
2.18 Mechanism of Arrhythmogenesis.....	71
2.19 Pacemaker and ICD.....	76
2.20 Atrial Fibrillation.....	84
2.21 Action Potential and Cardinal Ion Channels.....	89

## **SECTION 3    ATHEROSCLEROSIS    96–115**

3.1 Complication of Atherosclerosis.....	96
3.2 Special Cases of Atherosclerosis.....	98
3.3 Novel Risk Markers.....	99
3.4 Vascular Biology and Atherosclerosis.....	103
3.5 Risk Markers and Primary Prevention of Cardiovascular Diseases.....	108

## **SECTION 4    CARDIOMYOPATHY    116–146**

4.1 Arrhythmogenic Cardiomyopathy.....	116
4.2 Dilated Cardiomyopathy.....	119
4.3 Hypertrophic Cardiomyopathy.....	122
4.4 Left Ventricular Noncompaction.....	128
4.5 Myocarditis.....	129
4.6 Other Cardiomyopathies.....	134
4.7 Peripartum Cardiomyopathy.....	137
4.8 Restrictive Cardiomyopathy, Amyloidosis, and Sarcoidosis.....	139
4.9 Tachycardia-induced Cardiomyopathy.....	144
4.10 Takotsubo Cardiomyopathy: Stress Cardiomyopathy.....	145

**SECTION 5 CONGENITAL HEART DISEASES 147–243**

5.1	Truncus Arteriosus.....	147
5.2	Aortic Arch Anomalies and Vascular Ring.....	150
5.3	Anomalous Systemic Venous Connection.....	153
5.4	Complete AVSD.....	154
5.5	Coarctation of Aorta.....	159
5.6	Aortic Pulmonary Window.....	164
5.7	Conotruncal Anomalies.....	166
5.8	Congenital Coro Art Anomalies.....	168
5.9	Cong. Corrected TGA.....	173
5.10	Congenital AS.....	176
5.11	DORV.....	181
5.12	Duct Dependent Circulation.....	185
5.13	Ebstein's Anomaly.....	187
5.14	Eisenmenger Syndrome.....	191
5.15	Fontan Surgery.....	194
5.16	Hypoplastic Left Heart Syndrome.....	199
5.17	Fetal ECHO.....	202
5.18	Operability Assessment in LT ≥ RT shunt.....	204
5.19	Persistent LSVC.....	205
5.20	Interrupted Ao Arch.....	207
5.21	PA with Intact Vent Septum.....	209
5.22	Pulm Atresia with VSD.....	213
5.23	Congenital Pulm AV Fistula.....	217
5.24	Aneurysm of Sinus of Valsalva.....	219
5.25	Single Ventricle.....	222
5.26	Total Anomalous PV Connection.....	225
5.27	Tetralogy of Fallot.....	229
5.28	Cyanotic Congenital Heart Disease.....	234
5.29	TGA.....	239
5.30	Segmental Approach.....	242

**SECTION 6 ENDOCRINE SYSTEM 244–252**

6.1	Adrenal and CV disease.....	244
6.2	Amiodarone and Thyroid function.....	246
6.3	Endocrine Disorder and CV Disease.....	247
6.4	Parathyroid Disease.....	249
6.5	Pheochromocytoma.....	252

**SECTION 7 HEART FAILURE 253–319**

7.1	Left Vent Remodeling.....	253
7.2	Mechanical Circulation Support.....	258
7.3	Potential New Therapies for HF.....	264
7.4	Pathogenesis of Heart Failure.....	266
7.5	Sarcolemma Control of Calcium and Sodium.....	270
7.6	Heart Failure.....	272
7.7	Surgical Management of HF.....	274
7.8	Cardiopulmonary Exercise Test.....	276
7.9	Care of Patient with End Stage Heart Diseases.....	277
7.10	Contractile Cell and Protein.....	279
7.11	Device for Monitoring and Managing HF.....	282
7.12	Myocardial O <sub>2</sub> Uptake.....	284
7.13	Frank Starling Relationship.....	285

7.14 Cardiovascular Regeneration and Gene Therapy.....	287
7.15 HFrEF Management .....	290
7.16 HFpEF .....	298
7.17 Role of Ca <sup>++</sup> in Cardiac Cont. Relax Cycle.....	304
7.18 Adrenergic Signaling System.....	306
7.19 Acute Heart Failure .....	308
7.20 Cardiac Transplant .....	314
7.21 Devices for Monitoring HF.....	318
7.22 Biomarkers and Natriuretic Peptides .....	319

## **SECTION 8 HEMOSTATIC SYSTEM**

**320–336**

8.1 Antiplatelet Drugs.....	320
8.2 Hemostasis/Thrombosis/Fibrinolysis.....	328
8.3 Hypercoagulable States.....	332
8.4 NOACs .....	334

## **SECTION 9 HYPERTENSION**

**337–361**

9.1 Practical Clinical Approach to Evaluation and Management of Ambulatory Hypertensive Patients.....	337
9.2 BP in Acute CVA .....	339
9.3 Approach to Patient with Chest Pain .....	340
9.4 Central Ao Pr .....	341
9.5 Device Based Treatment for HTN.....	342
9.6 Diagnosis and Initial Evaluation.....	343
9.7 HTN in Pregnancy .....	345
9.8 Systemic HTN: Management.....	346
9.9 Hypertension: Mechanism and Diagnosis .....	350
9.10 Management of HTN and Sprint Trial .....	354
9.11 Pathogenesis of Hypertensive Heart Disease .....	355
9.12 HTN and Erectile Dysfunction .....	356
9.13 Secondary HTN .....	359

## **SECTION 10 INFECTIVE ENDOCARDITIS**

**362–374**

10.1 Cardiovascular Implantable Device INF.....	362
10.2 Infective Endocarditis Prophylaxis.....	364
10.3 Infective Endocarditis.....	365

## **SECTION 11 INTERVENTIONS**

**375–438**

11.1 Carotid Artery Stenting.....	375
11.2 Coronary Perforation .....	378
11.3 CTO Intervention.....	379
11.4 Drug-Eluting Balloons .....	380
11.5 Dedicated Bifurcation Stent.....	381
11.6 Deferred Stenting .....	383
11.7 Distal Protection Devices .....	384
11.8 Endomyocardial Biopsy .....	385
11.9 FFR.....	386
11.10 Fick's Principle .....	391
11.11 Hybrid Revascularization.....	395
11.12 IABP.....	396
11.13 In-Stent Restenosis .....	398
11.14 Intravascular Ultrasound .....	401
11.15 LA Appendage and Closure .....	404
11.16 Leadless Pacemaker .....	406

11.17	MitraClip and Percutaneous Mitral Valve .....	408
11.18	Optical Coherence Tomography .....	412
11.19	Other Modalities of Intravascular .....	415
11.20	Radiation Hazards .....	416
11.21	Renal Stenting and Denervation .....	418
11.22	Rotational Atherectomy .....	421
11.23	Stent Thrombosis .....	423
11.24	Subcutaneous Implantable Cardioverter-Defibrillator .....	424
11.25	Transcatheter Aortic Valve implantation .....	426
11.26	TIMI-MBG-NO flow .....	431
11.27	Valve Area Calculation .....	433
11.28	Measurement of Vascular Resistance.....	436
11.29	Wearable Implantable Cardioverter-Defibrillator .....	437

**SECTION 12 ISCHEMIC HEART DISEASES****439–496**

12.1	STEMI: Pathology, Pathophysiology, and Clinical Features.....	439
12.2	Approach to Patients with Chest Pain .....	441
12.3	Cardiogenic Shock.....	442
12.4	Coronary Blood Flow and Management Ischemia.....	444
12.5	Coronary Collateral Circulation.....	447
12.6	Coronary Flow Reserve .....	448
12.7	Heart Muscle and Causes of Myocardial Injury .....	451
12.8	LVF in STEMI .....	453
12.9	Determinants of Coronary Vascular Resistance .....	455
12.10	Metabolic Management in CAD .....	456
12.11	Metabolic and Functional Consequences of Ischemia.....	458
12.12	Physiological Assessment of Coro Art Stenosis.....	460
12.13	NSTE-ACS .....	461
12.14	Causes of MI without Coronary Atherosclerosis .....	468
12.15	Coronary Vasospasm.....	469
12.16	Pathophysiology of STEMI .....	470
12.17	Prinzmetal Angina .....	473
12.18	Reperfusion Injury .....	474
12.19	STEMI: Management .....	475
12.20	Risk Stratification Post-STEMI .....	482
12.21	Stable Ischemic Heart Disease .....	483
12.22	Regulation of Coronary Microcirculation .....	493
12.23	Stunned Myocardium.....	495

**SECTION 13 LIPID DISORDERS****497–518**

13.1	Pharmacological Management.....	497
13.2	Nutrition and CV Metabolic Disease .....	501
13.3	Statin Intolerance.....	502
13.4	Secondary Causes of Hyperlipidemia.....	504
13.5	2013 ACC/AHA Guidelines (Management and Lipids) .....	505
13.6	Lipoprotein Disorders.....	506
13.7	Non-HDL Cholesterol.....	510
13.8	LA(A) and SGLT2 .....	511
13.9	Emerging Therapies for Dyslipidemia Treatment.....	513
13.10	Lipoprotein Disorders and CV Disease.....	515
13.11	HOPE 3 Trial: Implication in India .....	518

<b>SECTION 14</b>	<b>MISCELLANEOUS</b>	<b>519–553</b>
14.1	CV Manifestation of Autonomic Disorders .....	519
14.2	Cocaine and Heart .....	525
14.3	Cardiorenal syndrome .....	527
14.4	Renal disease and CV Illness: Contrast Induced Nephropathy .....	530
14.5	Rheumatic Factor .....	533
14.6	Cardiovascular Abnormalities in HIV .....	539
14.7	Noncardiac Surgery in Cardiac Patients .....	541
14.8	Vascular Heart Disease .....	544
14.9	Ethanol and Heart .....	545
14.10	Traumatic Heart Disease .....	547
14.11	Rheumatic Disease and CV System .....	548
14.12	Vitamin D and Heart Disease .....	550
14.13	Ventriculoarterial Impedance (ZVA) .....	551
14.14	Exercise Cardiology .....	552
<b>SECTION 15</b>	<b>PERICARDIAL DISEASES</b>	<b>554–570</b>
15.1	Acute Pericarditis .....	554
15.2	Constrictive Pericarditis .....	557
15.3	Constrictive versus Restrictive .....	560
15.4	Pericardial Effusion and Tamponade .....	561
15.5	Pericardial Diseases .....	565
15.6	Relapsing and Recurrent Pericarditis .....	567
15.7	Specific Causes of Pericardial Disease .....	568
<b>SECTION 16</b>	<b>PERIPHERAL ARTERY DISEASE</b>	<b>571–578</b>
16.1	Acute Limb Ischemia .....	571
16.2	Peripheral Art Disease .....	573
16.3	Thromboangiitis Obliterans .....	578
<b>SECTION 17</b>	<b>PULMONARY DISEASES</b>	<b>579–595</b>
17.1	Sleep Apnea and Heart Disease .....	579
17.2	Pulmonary Embolism and Deep Vein Thrombosis .....	583
17.3	Pulmonary Hypertension .....	589
<b>SECTION 18</b>	<b>PREGNANCY AND HEART</b>	<b>596–600</b>
18.1	Pregnancy and Heart Disease .....	596
<b>SECTION 19</b>	<b>CLINICAL EXAMINATION</b>	<b>601–608</b>
19.1	Dynamic Auscultation .....	601
19.2	Hangout Interval .....	604
19.3	Second Heart Sound .....	605
19.4	History Taking and Physical Examination .....	608
<b>SECTION 20</b>	<b>ECG AND STRESS TEST</b>	<b>609–615</b>
20.1	Electrocardiography .....	609
20.2	Exercise testing .....	611
<b>SECTION 21</b>	<b>ECHO</b>	<b>616–628</b>
21.1	Intracardiac Flow Vortex Imaging .....	616
21.2	Speckle Tracking .....	618

21.3	3D-ECHO .....	621
21.4	Dobutamine Stress ECHO .....	623
21.5	TEE .....	625
21.6	ICE .....	626
21.7	Tissue Doppler Imaging.....	627

## **SECTION 22**    **NUCLEAR IMAGING**    **629–642**

22.1	Radionucleotide Ventriculography.....	629
22.2	Viability, Hibernation and Stunning.....	630
22.3	Nuclear Cardiology.....	634
22.4	Use of Nuclear Imaging.....	637

## **SECTION 23**    **CARDIAC CT MRI AND PLAQUE RUPTURE**    **643–652**

23.1	Plaque Rupture and Vulnerable Plaque .....	643
23.2	Cardiac Computed Tomography .....	645
23.3	Cardiovascular MRI .....	648

## **SECTION 24**    **TRIALS**    **653–687**

24.1	Amulet Study.....	653
24.2	Best (2015).....	654
24.3	Cantos Trial .....	655
24.4	AIDA .....	656
24.5	Castle AF .....	657
24.6	CAPTAF.....	658
24.7	Camera-MRI Trial.....	659
24.8	Viva Trial.....	660
24.9	Compass Trial.....	661
24.10	Clarify Study.....	662
24.11	Culprit Shock—2017.....	663
24.12	Champion Phoenix—2013 .....	664
24.13	Courage Trial .....	665
24.14	Cross Boss First Trial.....	666
24.15	Decision-CTO .....	667
24.16	Favor 2 Studies.....	668
24.17	Fame 1, 2 and 3 Trial.....	669
24.18	Forma Trial .....	672
24.19	Fourier .....	673
24.20	HOPE 3 Trial: Implication in India.....	674
24.21	Ilumien 3 Trial: Optimize PCI .....	675
24.22	Impact AF .....	677
24.23	Fourier Trial .....	678
24.24	Symlicity HTN-3 Trial .....	679
24.25	Partner 1 and 2 SURTAVI.....	680
24.26	Sentinel Trial.....	683
24.27	Prevail Trial.....	684
24.28	Orbita Trial .....	685
24.29	Noble Trial.....	686
24.30	Vampire 3 Trial.....	687

## **SECTION 25**    **RCT versus REGISTRIES**    **688**

<i>Index</i> .....	689
--------------------	-----